vs

Side-by-side financial comparison of CVRx, Inc. (CVRX) and PRO DEX INC (PDEX). Click either name above to swap in a different company.

PRO DEX INC is the larger business by last-quarter revenue ($18.7M vs $16.0M, roughly 1.2× CVRx, Inc.). PRO DEX INC runs the higher net margin — 11.7% vs -74.5%, a 86.2% gap on every dollar of revenue. On growth, PRO DEX INC posted the faster year-over-year revenue change (11.1% vs 4.4%). PRO DEX INC produced more free cash flow last quarter ($3.5M vs $-9.8M). Over the past eight quarters, CVRx, Inc.'s revenue compounded faster (22.0% CAGR vs 14.3%).

CVRx, Inc. is a commercial-stage medical technology company specializing in neuromodulation therapies for chronic cardiovascular diseases. Its flagship Barostim system treats heart failure and resistant hypertension, with core markets across North America and Europe, serving patients unresponsive to conventional drug treatments.

Pro Dex Inc is a precision manufacturing enterprise that produces custom machined components, subassemblies and finished products primarily for medical device original equipment manufacturers, as well as clients in the aerospace and industrial sectors, with its core operating market covering North America.

CVRX vs PDEX — Head-to-Head

Bigger by revenue
PDEX
PDEX
1.2× larger
PDEX
$18.7M
$16.0M
CVRX
Growing faster (revenue YoY)
PDEX
PDEX
+6.7% gap
PDEX
11.1%
4.4%
CVRX
Higher net margin
PDEX
PDEX
86.2% more per $
PDEX
11.7%
-74.5%
CVRX
More free cash flow
PDEX
PDEX
$13.3M more FCF
PDEX
$3.5M
$-9.8M
CVRX
Faster 2-yr revenue CAGR
CVRX
CVRX
Annualised
CVRX
22.0%
14.3%
PDEX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CVRX
CVRX
PDEX
PDEX
Revenue
$16.0M
$18.7M
Net Profit
$-11.9M
$2.2M
Gross Margin
86.3%
30.8%
Operating Margin
-69.8%
17.5%
Net Margin
-74.5%
11.7%
Revenue YoY
4.4%
11.1%
Net Profit YoY
-12.0%
7.2%
EPS (diluted)
$-0.45
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVRX
CVRX
PDEX
PDEX
Q4 25
$16.0M
$18.7M
Q3 25
$14.7M
$18.5M
Q2 25
$13.6M
$17.5M
Q1 25
$12.3M
$17.4M
Q4 24
$15.3M
$16.8M
Q3 24
$13.4M
$14.9M
Q2 24
$11.8M
$15.0M
Q1 24
$10.8M
$14.3M
Net Profit
CVRX
CVRX
PDEX
PDEX
Q4 25
$-11.9M
$2.2M
Q3 25
$-12.9M
$4.7M
Q2 25
$-14.7M
$1.2M
Q1 25
$-13.8M
$3.3M
Q4 24
$-10.7M
$2.0M
Q3 24
$-13.1M
$2.5M
Q2 24
$-14.0M
$1.6M
Q1 24
$-22.2M
$655.0K
Gross Margin
CVRX
CVRX
PDEX
PDEX
Q4 25
86.3%
30.8%
Q3 25
86.8%
29.0%
Q2 25
84.3%
19.9%
Q1 25
83.5%
33.3%
Q4 24
83.2%
30.2%
Q3 24
83.2%
34.6%
Q2 24
83.9%
27.2%
Q1 24
85.0%
28.0%
Operating Margin
CVRX
CVRX
PDEX
PDEX
Q4 25
-69.8%
17.5%
Q3 25
-83.5%
16.8%
Q2 25
-105.8%
7.7%
Q1 25
-108.8%
20.9%
Q4 24
-67.0%
16.0%
Q3 24
-97.3%
20.2%
Q2 24
-118.3%
15.6%
Q1 24
-206.4%
15.5%
Net Margin
CVRX
CVRX
PDEX
PDEX
Q4 25
-74.5%
11.7%
Q3 25
-87.6%
25.3%
Q2 25
-108.4%
6.8%
Q1 25
-111.5%
18.8%
Q4 24
-69.4%
12.1%
Q3 24
-98.0%
16.6%
Q2 24
-118.8%
10.6%
Q1 24
-206.0%
4.6%
EPS (diluted)
CVRX
CVRX
PDEX
PDEX
Q4 25
$-0.45
$0.66
Q3 25
$-0.49
$1.40
Q2 25
$-0.57
$0.33
Q1 25
$-0.53
$0.98
Q4 24
$-0.39
$0.61
Q3 24
$-0.57
$0.75
Q2 24
$-0.65
$0.44
Q1 24
$-1.04
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVRX
CVRX
PDEX
PDEX
Cash + ST InvestmentsLiquidity on hand
$75.7M
$6.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$39.3M
$41.6M
Total Assets
$104.8M
$62.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVRX
CVRX
PDEX
PDEX
Q4 25
$75.7M
$6.1M
Q3 25
$85.1M
$10.1M
Q2 25
$95.0M
$6.8M
Q1 25
$102.7M
$5.5M
Q4 24
$105.9M
$4.7M
Q3 24
$100.2M
$7.8M
Q2 24
$70.4M
$6.8M
Q1 24
$80.1M
$7.8M
Total Debt
CVRX
CVRX
PDEX
PDEX
Q4 25
Q3 25
Q2 25
$15.4M
Q1 25
Q4 24
Q3 24
Q2 24
$12.0M
Q1 24
Stockholders' Equity
CVRX
CVRX
PDEX
PDEX
Q4 25
$39.3M
$41.6M
Q3 25
$48.1M
$41.5M
Q2 25
$57.9M
$36.6M
Q1 25
$71.1M
$35.3M
Q4 24
$71.1M
$31.8M
Q3 24
$65.2M
$30.9M
Q2 24
$55.2M
$30.9M
Q1 24
$66.3M
$30.9M
Total Assets
CVRX
CVRX
PDEX
PDEX
Q4 25
$104.8M
$62.3M
Q3 25
$111.3M
$64.3M
Q2 25
$119.6M
$61.2M
Q1 25
$129.6M
$64.3M
Q4 24
$133.4M
$60.4M
Q3 24
$127.7M
$54.3M
Q2 24
$96.0M
$52.5M
Q1 24
$106.2M
$50.5M
Debt / Equity
CVRX
CVRX
PDEX
PDEX
Q4 25
Q3 25
Q2 25
0.42×
Q1 25
Q4 24
Q3 24
Q2 24
0.39×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVRX
CVRX
PDEX
PDEX
Operating Cash FlowLast quarter
$-9.8M
$3.6M
Free Cash FlowOCF − Capex
$-9.8M
$3.5M
FCF MarginFCF / Revenue
-61.3%
18.8%
Capex IntensityCapex / Revenue
0.4%
0.4%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters
$-40.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVRX
CVRX
PDEX
PDEX
Q4 25
$-9.8M
$3.6M
Q3 25
$-9.7M
$2.3M
Q2 25
$-7.9M
$-173.0K
Q1 25
$-12.8M
$754.0K
Q4 24
$-8.0M
$-4.2M
Q3 24
$-10.4M
$1.9M
Q2 24
$-9.8M
$1.0M
Q1 24
$-10.9M
$4.1M
Free Cash Flow
CVRX
CVRX
PDEX
PDEX
Q4 25
$-9.8M
$3.5M
Q3 25
$-10.0M
$2.2M
Q2 25
$-8.0M
Q1 25
$-12.9M
$574.0K
Q4 24
$-8.1M
$-4.7M
Q3 24
$-10.4M
$1.5M
Q2 24
$-10.2M
Q1 24
$-11.8M
$4.0M
FCF Margin
CVRX
CVRX
PDEX
PDEX
Q4 25
-61.3%
18.8%
Q3 25
-68.1%
11.9%
Q2 25
-59.2%
Q1 25
-104.3%
3.3%
Q4 24
-52.5%
-27.9%
Q3 24
-78.1%
9.8%
Q2 24
-86.3%
Q1 24
-109.7%
27.7%
Capex Intensity
CVRX
CVRX
PDEX
PDEX
Q4 25
0.4%
0.4%
Q3 25
2.0%
0.5%
Q2 25
0.8%
Q1 25
0.9%
1.0%
Q4 24
0.3%
3.2%
Q3 24
0.3%
2.9%
Q2 24
3.0%
Q1 24
8.5%
0.8%
Cash Conversion
CVRX
CVRX
PDEX
PDEX
Q4 25
1.63×
Q3 25
0.49×
Q2 25
-0.14×
Q1 25
0.23×
Q4 24
-2.03×
Q3 24
0.77×
Q2 24
0.66×
Q1 24
6.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVRX
CVRX

US$14.9M93%
Other$1.1M7%

PDEX
PDEX

Segment breakdown not available.

Related Comparisons